Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illumina, Inc. (ILMN) vs Paychex, Inc. (PAYX) Price & Performance

Illumina, Inc.Trade
Paychex, Inc.Trade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs Paychex, Inc. — how do they compare? Illumina, Inc. trades at $266.99 (market cap $39.95B), while Paychex, Inc. trades at $104.29 (market cap $37.19B). The key difference: Illumina, Inc. and Paychex, Inc. are close in size by market cap, and Paychex, Inc. pays a 4.56% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Paychex, Inc. for 56 Days on average.

ILMNPAYX
Market Cap
$39.95B$37.19B
Volume
3,169,5033,344,316
Sector
HealthIndustrials
52-Week High
$293.69$128.59
52-Week Low
$91.00$85.57
Typical Hold Time
83 Days56 Days
Enterprise Value
$41.31B$40.87B
Dividend Yield
—4.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.

The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.

Paychex, Inc.

Paychex (PAYX) trades at $101.55, up 0.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 27.35% net income margin and a 47.06% ROE, but valuation metrics like a P/E of 20.15 and P/S of 5.52 suggest a premium. Recent news highlights concerns over dividend sustainability and a 14% stock decline, even as the company reported double-digit earnings growth driven by PEO and insurance segments.

The outlook is mixed: solid fundamentals and a consensus price target of $111.00 imply upside, but bearish technicals and investor skepticism about growth levers like AI pose risks. Key opportunities include consistent dividend payments and market leadership, while risks involve labor market sensitivity and high debt levels following a significant increase in total liabilities.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ILMN
96% Buy4% Sell
Avg holding period · 83 Days
PAYX

No sentiment data available yet.

Top news

Latest headlines on both assets

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN →

About Paychex, Inc.

Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.

Read more on PAYX →